Boehringer Ingelheim (BI) is expanding its global Pharmacometrics (PMx) group in Biberach, Germany and Ridgefield, CT.
As a pharmacometrician with BI you act as a standing member in early and late phase clinical drug development teams working closely together with experts in the fields of medicine, clinical pharmacology, biomarker, clinical development, and statistics. Pharmacometricians with the necessary experience and skill set will have the opportunity to act as leader ("integrator") of those Early Clinical Development Teams and Clinical Pharmacology and Biomarker Teams. In addition to your role as a Project Pharmacometrician supporting one or multiple projects, BI PMx offers two career development tracks (focus areas). One of them focuses on strategic PMx support of clinical drug development programs (i.e., model-informed drug discovery and development (MID3)). The other one focuses on methodological and technical PMx work (i.e., performing hands-on PMx analysis and developing and evaluating new PMx approaches and methods). Pharmacometricians are assigned to drug development projects approximately two years before first-in-man clinical trials and support projects until successful regulatory approval and beyond. BI PMx applies a question-based fit-for-purpose approach to inform drug development with state-of-the-art PMx approaches that include but are not limited to non-linear mixed effects models, physiological-based pharmacokinetic models, and quantitative systems pharmacology models. Links USA: http://d.rfer.us/BIRixl8Y3 http://d.rfer.us/BIREj08Y6 Link Germany: https://tas-boehringer.taleo.net/careersection/global+template+career+section+28external29/jobdetail.ftl?job=174013 Tasks & Responsibilities * Development and implementation of a model-informed drug discovery and development (MID3) strategy for clinical drug development projects * Planning, execution, and reporting of a wide variety of pharmacometric analyses on a clinical trial and clinical drug development project level * Development and implementation of innovative pharmacometrics approaches for supporting decision making in clinical drug development and regulatory approval including but not limited to non-linear mixed effects models, physiological-based pharmacokinetic models, and quantitative systems pharmacology models * Leading a team of pharmacometricians, Early Clinical Development Teams, or Clinical Pharmacology and Biomarker Teams Requirements * PhD in Medicine, Pharmaceutics, Mathematics, Statistics, Systems Pharmacology, Biology or equivalent area of focus with experience in pharmacometrics in pre-clinical or clinical drug development (pharmaceutical industry, academia or regulatory agency) * Demonstrated competence with relevant data analysis software such as NONMEM, Monolix, R, SAS, MATLAB, PBPK software, SimBiology. * Proficient knowledge in clinical pharmacology and model informed drug discovery and development * For Senior Level Positions: o Demonstrated consistent high quality MID3 contributions to clinical drug development projects at different phases of clinical drug development (strategic and operational) o Successful track record of managing and developing direct reports If you have questions, please do not hesitate to contact, Recruiting Services, Germany, Biberach: Agnes Woyke, Email: agnes.wo...@boehringer-ingelheim.com<mailto:agnes.wo...@boehringer-ingelheim.com> Director Pharmacometrics, USA, Ridgefield: Benjamin Weber, Email: benjamin.we...@boehringer-ingelheim.com<mailto:benjamin.we...@boehringer-ingelheim.com> [esig-bi-logo-sm.png]<http://bit.ly/OJRIa8> Benjamin Weber, PhD Director, Pharmacometrics Translational Medicine & Clinical Pharmacology Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, Connecticut P: 203-791-6240 benjamin.we...@boehringer-ingelheim.com<mailto:benjamin.we...@boehringer-ingelheim.com> [icon-twitter.gif]<http://bit.ly/LO4IvZ>[icon-linkedin.gif]<http://linkd.in/LO4tAP> [icon-youtube.gif] <http://bit.ly/PJCrqF> CONFIDENTIALITY NOTICE: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure of distribution is prohibited. If you are not the intended recipient, please contact sender by reply e-mail and destroy all copies of the original message.